Intraosseous Access: Sites, Needle Selection and Step-by-Step Technique
Quick Answer
Intraosseous (IO) access places a needle into the marrow cavity of a bone so drugs and fluids can reach the circulation when a peripheral IV can’t be placed quickly. In adult cardiac arrest, the 2025 AHA guidelines recommend trying IV access first and moving to IO if IV attempts fail or aren’t feasible, while in children either route is acceptable depending on availability, expertise and timeliness. The proximal tibia and proximal humerus are the usual adult sites. Extravasation is the most common complication and can lead to compartment syndrome if it goes unnoticed, and the needle should come out once other access is secured, ideally within 24 hours.
When Is Intraosseous Access Indicated?
IO access is indicated when a patient needs vascular access now and a peripheral IV can’t be placed in time. LITFL’s intraosseous access page lists failed IV access in trauma, burns, shock or resuscitation, and use as a temporizing measure until definitive access is in place.
A joint ENA and INS position statement describes IO as the first alternative when peripheral access can’t be obtained or attempts fail. The same statement calls it a reasonable first attempt in patients already known to have limited vascular access.
Cardiac arrest is where the guidance is most specific. The 2025 AHA adult advanced life support guidelines recommend attempting IV access first for drug administration (Class 1, Level A). IO access is reasonable if initial IV attempts are unsuccessful or not feasible (Class 2a, Level A).
Children are handled differently. The 2025 AHA pediatric advanced life support guidelines recommend rapid IV or IO access in pediatric cardiac arrest and tell clinicians to choose the first route based on availability, expertise and timeliness, noting that no studies have compared the two routes in this group. For children in decompensated shock, the Royal Children’s Hospital Melbourne guideline recommends IO when venous access attempts fail or would take more than 90 seconds.
Who Can Place an IO Line in the Field
The 2019 National EMS Scope of Practice Model places intraosseous initiation, in pediatric or adult patients, at the AEMT and Paramedic levels. It also states that each state determines the scope of practice of its licensed EMS personnel.
Data from the AEMT level are reassuring. After Vermont extended adult IO access to AEMTs in 2014, a statewide study of AEMT adult IO covering 543 adults found success rates of 95.2% for AEMTs and 95.6% for paramedics, within the authors’ non-inferiority margin.
Whether you place IO lines, in which patients, at which sites and with which device depends on your state protocols and your medical director. Use everything below as background for your own protocol.
IO vs IV: What the 2024–2025 Trials Show
According to the 2025 AHA adult guidelines, three recent large randomized trials compared IO-first with IV-first access in adult out-of-hospital cardiac arrest and found no difference in clinical outcomes. The two largest were both published in the New England Journal of Medicine.
In the PARAMEDIC-3 trial, 6,082 patients were assigned to an IO-first or IV-first strategy. At 30 days, 4.5% (137 of 3,030) of the IO group and 5.1% (155 of 3,034) of the IV group were alive. Return of spontaneous circulation at any time occurred in 36.0% versus 39.1%, and a favorable neurologic outcome at discharge in 2.7% versus 2.8%.
The IVIO trial randomized 1,479 adults. Sustained ROSC was 30% with IO and 29% with IV (relative risk 1.06; 95% CI, 0.90–1.24), and 30-day survival was 12% versus 10% (relative risk 1.16; 95% CI, 0.87–1.56).
| Trial | Patients | ROSC (IO vs IV) | 30-day survival (IO vs IV) |
|---|---|---|---|
| PARAMEDIC-3 (Couper 2025) | 6,082 | Any ROSC 36.0% vs 39.1% | 4.5% vs 5.1% |
| IVIO (Vallentin 2024) | 1,479 | Sustained ROSC 30% vs 29% | 12% vs 10% |
When ILCOR pooled the randomized trials, survival to discharge and survival with a favorable neurologic outcome did not differ, but the odds of sustained ROSC were lower with IO (OR 0.89; 95% CI, 0.80–0.99), as summarized in the AHA guideline. The guideline writers also caution that finding no outcome difference does not show the two routes are equivalent. That is where the 2025 recommendation lands: IV first, IO when IV fails or isn’t feasible.
The drug may matter as well as the route. In a prespecified secondary analysis of the ALPS trial, IV amiodarone improved survival to discharge compared with placebo (adjusted RR 1.26; 95% CI, 1.06–1.50), as did IV lidocaine (adjusted RR 1.21; 95% CI, 1.02–1.45), while neither drug showed a benefit by the IO route (adjusted RR 0.94 and 1.03). Route was not randomized and the interaction was not statistically significant, so the authors describe the finding as not clinically definitive and call for prospective study.
Intraosseous Contraindications
Most contraindications apply to the target bone or limb, so they usually mean choosing another site. The list below combines the 2016 systematic review of adult IO access, the CMAJ review, the ENA and INS statement, the RCH guideline and LITFL.
- A fracture in the target bone, or a suspected fracture proximal to the site in the same limb.
- A vascular injury in the same limb.
- Infection or cellulitis over the site.
- A previous IO attempt or IO line in the same bone. CMAJ uses a 24-hour window, and the ENA and INS statement uses 48 hours.
- Previous surgery or orthopedic hardware in the target bone.
- Compartment syndrome in the target limb.
- Bone disease such as osteogenesis imperfecta or osteopetrosis.
- Landmarks you can’t identify.
Burns are a point of disagreement. The 2016 review lists a burn over the site as a contraindication, while the RCH guideline says a burn is not one but advises choosing an unburned site when you can.
IO Insertion Sites in Adults
The proximal tibia and proximal humerus are the two main adult sites. The ENA and INS statement calls the proximal tibia widely preferred for its flat surface and accessibility, notes that the proximal humerus is increasingly popular, and lists the distal tibia, distal femur, iliac crest and sternum as additional sites.
| Site | Landmark | Positioning and angle | Watch for |
|---|---|---|---|
| Proximal humerus | Greater tubercle; don’t insert medial to it, which risks the biceps tendon (Petitpas 2016) | Arm adducted and internally rotated, hand over the abdomen; about 45 degrees, aiming toward the opposite hip (EZ-IO guide) | Dislodgement; don’t raise the arm above 45 degrees after insertion (EZ-IO guide) |
| Proximal tibia | About 2 cm below the tibial tuberosity and 1–2 cm medial, on the flat surface (Petitpas 2016) | Perpendicular to the bone (EZ-IO guide) | UK Defence guidance avoids it when pelvic or intra-abdominal bleeding is suspected |
| Distal tibia | Flat medial surface, 2 cm (Petitpas 2016) to about 3 cm (EZ-IO guide) above the medial malleolus | Perpendicular to the bone (EZ-IO guide) | Listed as an additional site by ENA and INS |
| Sternum | Needs a sternal-specific device such as FAST1; the EZ-IO guide says not to use EZ-IO here | Per device | Thin medullary cavity with a risk of passing through the bone toward the aorta and heart (Petitpas 2016) |
The tibial caution comes from the UK Defence Medical Services IO guideline, which prefers the proximal humerus in adults and avoids the proximal tibia when pelvic or intra-abdominal bleeding is suspected. Your protocol names your preferred site.
Humeral vs Tibial IO
The humerus has had a mixed record in prehospital studies. In a randomized trial in out-of-hospital cardiac arrest of 182 patients, first-attempt success was 91% for tibial IO, 51% for humeral IO and 43% for peripheral IV, and time to access was 4.6 minutes for the tibia, 7.0 for the humerus and 5.8 for IV.
Dislodgement is part of the humeral problem. The 2016 systematic review reports dislodgement in 20% of humeral insertions in one prehospital trial and notes that strapping the arm reduces it.
Other data are kinder to the humerus. In a 2012 study of paramedic humeral IO, paramedics attempted humeral access in 247 of 405 cardiac arrests, with 91% first-attempt success, 94% overall success and 2% dislodgement after successful placement.
IVIO assigned its IO patients to humeral (361) or tibial (370) access. According to the ACC summary of the IVIO trial, success within two attempts was 90% humeral versus 93% tibial, and sustained ROSC was 30% versus 31%. In a nonrandomized subset with CT imaging, the catheter was correctly positioned in 71% of 32 humeral and 100% of 35 tibial insertions, a finding the summary calls hypothesis-generating.
| Study | Humeral | Tibial |
|---|---|---|
| Reades 2011 (RCT, 182 adult cardiac arrests) | 51% first-attempt success; 7.0 min to access | 91% first-attempt success; 4.6 min to access |
| Wampler 2012 (247 humeral attempts) | 91% first-attempt success; 2% dislodged after placement | Not studied |
| IVIO (731 patients in the IO arm) | 90% success within two attempts; sustained ROSC 30%; correct position on CT 71% (n=32) | 93% success within two attempts; sustained ROSC 31%; correct position on CT 100% (n=35) |
Pediatric IO Sites
The RCH guideline gives landmarks by age, and it directs the needle perpendicular to the bone and away from the growth plate.
- The proximal tibia site is on the flat anteromedial surface, about 1 cm (one finger breadth) below the tibial tuberosity in neonates and young children and about 2 cm below it in older children.
- The distal femur site is about 1 cm above the superior border of the patella and 1–2 cm medial to the midline, with the leg held extended.
- The distal tibia site is 1–2 cm proximal to the medial malleolus.
- The humerus is used when landmarks are easy to identify, usually over 7 years of age, with the hand on the abdomen, the elbow flexed and the shoulder internally rotated. The needle goes in about 1 cm above the surgical neck on the most prominent part of the greater tubercle.
IO Devices and Needle Sizes
LITFL and the 2016 review describe powered drivers such as EZ-IO, manual needles such as the Jamshidi or Cook needle, and impact-driven devices such as the BIG, and the UK Defence guideline covers the sternal FAST1. The ENA and INS statement cites evidence that powered drivers insert faster than manual or impact devices.
For EZ-IO, the EZ-IO manufacturer pocket guide lists three needle sets: 15 mm for patients 3–39 kg, 25 mm for patients 3 kg and up, and 45 mm for patients 40 kg and up. It tells you to choose based on patient weight, anatomy and the tissue depth over the site. LITFL suggests the 45 mm needle for the humerus or for patients with excess soft tissue.
The check that matters at the bedside is the black line. With the needle tip resting on bone, the manufacturer guide says the 5 mm mark closest to the hub must be visible above the skin, and the RCH guideline asks for at least one black line visible outside the skin before drilling. If you can’t see it, the needle is too short for that site.
How to Place an IO Line, Step by Step
The steps below follow a powered driver such as EZ-IO and combine the 2016 systematic review, the RCH guideline, LITFL, CMAJ and the manufacturer guide. Where your protocol or device instructions differ, follow them.
- Confirm that IO access is indicated and that no contraindication applies to the bone you’ve chosen.
- Prime the extension set with saline.
- Position the limb and identify the landmark for your site.
- Clean the skin with antiseptic.
- Push the needle through the skin until the tip touches bone, perpendicular to the bone at the tibia or femur and at about 45 degrees toward the opposite hip at the humerus.
- Check that the 5 mm black line is visible above the skin, and switch to a longer needle if it isn’t.
- Drill through the cortex and stop when you feel a give or loss of resistance.
- Hold the hub steady and remove the stylet.
- Aspirate marrow if you need blood samples.
- If the patient is awake, give lidocaine as your protocol directs, following the sequence described below.
- Attach the primed extension set.
- Flush with saline while watching the site for swelling.
- Secure the needle and start the infusion under pressure.
- Record the date and time of insertion.
The 2016 review lists the signs of correct placement: a sudden loss of resistance on entering the marrow cavity, a needle that stays upright without support, marrow or blood that aspirates easily, and a flush that goes in without subcutaneous swelling. Marrow can’t always be aspirated, and the RCH guideline notes that a correctly placed line should still flush easily.
Flush volumes differ slightly between sources. CMAJ and LITFL use a 10 mL saline flush, and the manufacturer guide gives 5–10 mL for adults and 2–5 mL for infants and children, noting that more than one flush may be needed. At the humerus, strap the arm to the body to reduce dislodgement.
Pain Control in the Awake Patient
In healthy volunteers, the flush hurt more than the insertion. In small, manufacturer-sponsored volunteer studies summarized by a BestBETs review of lidocaine for IO pain, insertion pain averaged 3.0–4.4 out of 10, while flush pain averaged 4.6–7.9 out of 10 even with lidocaine.
The dose most often published, in an ACEP Now article on IO myths and in the manufacturer guide, is 40 mg of preservative-free 2% lidocaine for adults and 0.5 mg/kg (maximum 40 mg) for children. Both describe infusing it slowly over 120 seconds and letting it dwell for 60 seconds before the infusion starts.
The manufacturer guide gives a specific order for EZ-IO. Flush the catheter with saline, attach the lidocaine syringe directly to the hub without the extension set, infuse the dose over 120 seconds and let it dwell for 60 seconds. Then attach the saline-primed extension set and flush, and if pain persists, give half the initial dose over 60 seconds.
The evidence behind this is thin. The 2016 review found that about half of patients given 20–40 mg of lidocaine still reported pain during later drug or fluid administration, and the ENA and INS statement recommends lidocaine while citing a review that found little evidence of efficacy. Your protocol sets the dose.
Flow Rates, Drugs and Blood Samples
IO flow depends heavily on pressure. The 2016 review reports that flow can reach about 150 mL/min at the tibia or humerus with a pressure bag, and the two studies in its flow table show how much pressure adds.
| Study (from Petitpas 2016) | Site | Gravity (mL/min) | Pressure bag at 300 mmHg (mL/min) |
|---|---|---|---|
| Ong 2009 | EZ-IO, tibia | 73 ± 35 | 165 ± 112 |
| Ong 2009 | EZ-IO, humerus | 84 ± 38 | 153 ± 65 |
| Hammer 2015 | EZ-IO, tibia | 27 ± 5 | 69 ± 54 |
| Hammer 2015 | EZ-IO, humerus | 16 ± 3 | 60 ± 44 |
| Hammer 2015 | FAST1, sternum | 53 ± 2 | 112 ± 47 |
The review states that, in theory, any drug that can be given IV can be given IO. Its list includes epinephrine, amiodarone, adenosine, vasopressors, induction agents, blood products and contrast media, and it recommends following each drug with a 10 mL flush.
IO blood can go to the lab with caveats. In hemodynamically stable patients, the review found IO and IV values similar for sodium, glucose, lactate, blood gases and hemoglobin, with potassium less accurate but within 25%. Samples drawn during cardiac arrest or during an infusion are less reliable.
Complications and How Long an IO Can Stay In
Extravasation is the most common complication, and the CMAJ review warns that it can lead to compartment syndrome if it goes undetected. Other complications include infection (cellulitis, abscess or osteomyelitis) and fracture, and the RCH guideline adds through-and-through penetration of the bone and, in children, growth plate injury.
Serious complications are uncommon. The 2016 review puts IO complications at under 1% of insertions, links osteomyelitis to prolonged use, and reports that the most serious complications, including deaths, involved sternal access.
Long-term harm looks rare too. A 2025 nationwide Danish study followed 5,012 patients for 180 days after prehospital IO access and found long-term complications in fewer than 0.1% of cases, with none in children.
Watch the site and the limb. CMAJ advises checking for extravasation after insertion, and the RCH guideline calls for neurovascular observations on any limb with an IO attempt until 24 hours after removal.
The IO is a bridge to other access. The ENA and INS statement notes that the FDA limits IO dwell time to 24 hours, with specific devices allowed up to 48 hours in total when no other access is available, and the manufacturer guide allows EZ-IO extension to 48 hours in patients 12 and older. CMAJ advises removing the needle once peripheral or central access is secured, ideally within 24 hours.
Keeping the IO Skill Ready
Procedures you don’t perform often fade without rehearsal, a problem we covered in our episode on procedural skill decay. IO insertion is no exception.
How you practice may matter. In a randomized education trial in EMS providers, 48 participants learned pediatric resuscitation skills either in four weekly sessions or over two consecutive days. Three months later, IO insertion scores were still above baseline in the spaced group (2.5 to 3.1, P=.04) but not in the massed group (2.6 to 2.7, P=.98).
That supports short, repeated rehearsal, such as finding the greater tubercle by feel and running the lidocaine-and-flush sequence on the device your service carries. Be clear about what practice does, though. Simulation builds familiarity and confidence. It doesn’t replace supervised experience or your agency’s credentialing, and its link to patient outcomes is still limited, as the founder discussed in the evidence on simulation and patient outcomes.
FAQ
Can you give blood through IO access?
Yes. Blood products are among the infusions listed in the 2016 systematic review of adult IO access, and a pressure bag improves flow.
What drugs can be given via the intraosseous route?
In theory, any drug that can be given IV can be given IO, including epinephrine, amiodarone, adenosine and vasopressors. Follow each drug with a 10 mL saline flush.
Is IO better than IV in cardiac arrest?
Not on current evidence: two large randomized trials found no survival difference, and pooled data showed slightly lower odds of sustained ROSC with IO. The 2025 AHA guidelines recommend IV first in adults, with IO when IV fails or isn’t feasible.
Which IO needle length should I use?
Choose by weight and tissue depth so the 5 mm black line is visible above the skin with the tip on bone. For EZ-IO, the manufacturer lists 15 mm for 3–39 kg and 45 mm for 40 kg and up, with the 25 mm set for patients 3 kg and up.
How long can an IO stay in?
The FDA limit is 24 hours, and some devices may stay up to 48 hours when no other access is available. Remove it as soon as peripheral or central access is secured.
Can EMTs place an IO?
The 2019 National EMS Scope of Practice Model places IO initiation at the AEMT and Paramedic levels, not the EMT level. Your state sets the actual scope, so check your protocols.
Conclusion
IO access gets drugs and fluid into the circulation when veins won’t cooperate, and serious complications are uncommon when the needle sits in the marrow cavity and comes out on time. In adult cardiac arrest, the 2024–2025 trials and the 2025 AHA guidelines put IV first and IO as the fallback, while children can get whichever route is fastest in your hands.
At the bedside, confirm the 5 mm mark before you drill, and expect the first flush in an awake patient to be the painful part.
If IO access is in your protocol, the EMS Procedural Training course pairs a step-by-step IO module with simulation models you keep, alongside the course’s airway and chest procedures.
References
- American Heart Association. Part 9: Adult advanced life support: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025. doi:10.1161/CIR.0000000000001376. https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/adult-advanced-life-support
- American Heart Association; American Academy of Pediatrics. Part 8: Pediatric advanced life support: 2025 American Heart Association and American Academy of Pediatrics Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025. doi:10.1161/CIR.0000000000001368. https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/pediatric-advanced-life-support
- Couper K, Ji C, Deakin CD, et al. A randomized trial of drug route in out-of-hospital cardiac arrest. N Engl J Med. 2025;392(4):336-348. doi:10.1056/NEJMoa2407780. PubMed: https://pubmed.ncbi.nlm.nih.gov/39480216/
- Vallentin MF, Granfeldt A, Klitgaard TL, et al. Intraosseous or intravenous vascular access for out-of-hospital cardiac arrest. N Engl J Med. Published online October 31, 2024. doi:10.1056/NEJMoa2407616. PubMed: https://pubmed.ncbi.nlm.nih.gov/39480221/
- American College of Cardiology. Intravenous vs. intraosseous vascular access during out-of-hospital cardiac arrest (IVIO). Clinical trial summary. November 6, 2024. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2024/11/06/18/48/ivio
- Daya MR, Leroux BG, Dorian P, et al. Survival after intravenous versus intraosseous amiodarone, lidocaine, or placebo in out-of-hospital shock-refractory cardiac arrest. Circulation. 2020;141(3):188-198. doi:10.1161/CIRCULATIONAHA.119.042240. PubMed: https://pubmed.ncbi.nlm.nih.gov/31941354/
- Petitpas F, Guenezan J, Vendeuvre T, Scepi M, Oriot D, Mimoz O. Use of intra-osseous access in adults: a systematic review. Crit Care. 2016;20:102. doi:10.1186/s13054-016-1277-6
- Rosenberg H, Cheung WJ. Intraosseous access. CMAJ. 2013;185(5):E238. doi:10.1503/cmaj.120971
- Mohr JK, Proud ME. The Role of the Registered Nurse in the Use of Intraosseous Vascular Access Devices. Joint position statement. Emergency Nurses Association and Infusion Nurses Society; 2020 (developed 2019). https://www.ena.org/sites/default/files/2025-08/The%20Role%20of%20the%20Registered%20Nurse%20in%20the%20Use%20of%20Intraosseous%20Vascular%20Access%20Devices.pdf
- The Royal Children’s Hospital Melbourne. Clinical Practice Guidelines: Intraosseous access. Updated December 2024. https://www.rch.org.au/clinicalguide/guideline_index/intraosseous_access/
- Nickson C. Intraosseous access. Life in the Fast Lane (LITFL). Updated November 8, 2024. https://litfl.com/intraosseous-access/ (expert opinion)
- National Association of State EMS Officials. National EMS Scope of Practice Model 2019 (Report No. DOT HS 812 666). National Highway Traffic Safety Administration; 2019. https://ems.gov/assets/National_EMS_Scope_of_Practice_Model_2019.pdf
- Wolfson DL, Tandoh MA, Jindal M, Forgione PM, Harder VS. Adult intraosseous access by advanced EMTs: a statewide non-inferiority study. Prehosp Emerg Care. Published online August 5, 2016. doi:10.1080/10903127.2016.1209262
- Defence Medical Services. Intraosseous (IO) access. Clinical Guidelines for Operations. Updated July 1, 2026. https://cgo.mod.uk/clinical-guidelines-for-operations/resuscitation-procedures/intraosseous-io-access/
- Reades R, Studnek JR, Vandeventer S, Garrett J. Intraosseous versus intravenous vascular access during out-of-hospital cardiac arrest: a randomized controlled trial. Ann Emerg Med. 2011;58(6):509-516. doi:10.1016/j.annemergmed.2011.07.020. PubMed: https://pubmed.ncbi.nlm.nih.gov/21856044/
- Wampler D, Schwartz D, Shumaker J, Bolleter S, Beckett R, Manifold C. Paramedics successfully perform humeral EZ-IO intraosseous access in adult out-of-hospital cardiac arrest patients. Am J Emerg Med. 2012;30(7):1095-1099. doi:10.1016/j.ajem.2011.07.010
- Teleflex. Arrow EZ-IO Intraosseous Vascular Access System Pocket Guide. MC-000280 Rev 4. September 2022. https://www.teleflex.com/usa/en/product-areas/emergency-medicine/intraosseous-access/arrow-ez-io-system/features-and-benefits/Arrow_EZIO_PocketGuide.pdf (manufacturer guidance)
- BestBETs. Local anaesthetics in intraosseous access. Best Evidence Topics. https://www.bestbets.org/bets/bet.php?id=2515
- Sampson C. Intraosseous myths: what ED docs should know about this IV alternative. ACEP Now. January 22, 2021. https://www.acepnow.com/article/intraosseous-myths-what-ed-docs-should-know-about-this-iv-alternative/ (expert opinion)
- Petersen LB, Bogh SB, Hansen PM, et al. An assessment of long-term complications following prehospital intraosseous access: a nationwide study. Resuscitation. 2025;206:110454. doi:10.1016/j.resuscitation.2024.110454. PubMed: https://pubmed.ncbi.nlm.nih.gov/39645023/
- Patocka C, Cheng A, Sibbald M, et al. A randomized education trial of spaced versus massed instruction to improve acquisition and retention of paediatric resuscitation skills in emergency medical service (EMS) providers. Resuscitation. 2019;141:73-80. doi:10.1016/j.resuscitation.2019.06.010